MedTrace Logo

Prediction of ARrhythmic Events With Positron Emission Tomography II

NCT03493516 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 302

Last updated 2026-03-06

No results posted yet for this study

Summary

Sudden cardiac death continues to be a major contributor to mortality in patients with ischemic cardiomyopathy. While implantable defibrillators can prevent death from ventricular arrhythmias, our current approach to identify patients at highest risk primarily rests on demonstrating a reduction in left ventricular ejection fraction less than 35%. The purpose of this observational cohort study is to prospectively test whether this can be enhanced by quantifying the amount of sympathetic denervation, left ventricular end-diastolic volume or brain natriuretic peptide levels.

Conditions

  • Sudden Cardiac Arrest
  • Ischemic Cardiomyopathy
  • Congestive Heart Failure

Interventions

DIAGNOSTIC_TEST

PET scan quantifying sympathetic denervation using [18F]-LMI1195

A cardiac PET scan will be obtained to quantify the percentage of the left ventricle that is denervated and has reduced uptake of the sympathetic nerve tracer \[18F\]-LMI1195

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Lantheus Medical Imaging

    collaborator INDUSTRY

  • State University of New York at Buffalo

    lead OTHER

Principal Investigators

  • John M Canty, MD · University at Buffalo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-08
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03493516 on ClinicalTrials.gov